Business Wire

KidKraft Announces Appointment of Todd Whitbeck as Chief Financial Officer

Share

KidKraft, Inc. (“KidKraft”) announced today Todd Whitbeck, a seasoned executive with more than 30 years of experience in finance and corporate development, has been appointed Chief Financial Officer effective immediately.

Whitbeck has a proven track record of financial expertise and operational leadership across a diverse background of public and private companies, with previous success working with MidOcean Partners, the private equity firm that owns KidKraft. He will oversee global financial operations and work closely with KidKraft’s CEO on continued growth and international expansion as the company builds on a 50-year legacy in the toy and juvenile product industry. Whitbeck will report directly to Geoff Walker, Chief Executive Officer.

“Todd is a seasoned finance executive and his leadership will help drive KidKraft’s growth strategies,” said Geoff Walker, CEO, KidKraft. “I’m excited for his partnership and to welcome him as a key member of our executive team.”

“I look forward to working with Geoff and the team at KidKraft and to leveraging my prior experience to fuel the company’s growth,” said Todd Whitbeck. “Having worked across many industries throughout my career, it’s refreshing after all these years to work with a company that inspires the imaginations of children who will lead future generations.”

Whitbeck was most recently CFO and Head of Business Development, Sales, Marketing and Administrative Functions for CANarchy, a fast-growing collective of local, regional and national craft beer breweries. Previously he was Executive Vice President, CFO & Business Development for Water Pik, Inc. where he led and facilitated a very successful sale of the company, and subsequently led integration efforts for the combined companies. He was CFO for JP Energy, Sears Holdings Corporation (SHC) in the hard goods business units and off-mall retail selling formats, and CompUSA, where he elevated his oversight to CFO through various finance roles as the company grew and was acquired. He is a board member for Tufts Health Plan Board of Directors.

An industry leader in design and development of children’s toys and furniture, KidKraft is focused on inspiring imaginative play experiences through high quality products. The company's innovative portfolio includes dollhouses, play kitchens, outdoor playsets, children's furniture, wooden dolls and vehicles and more, offering a variety of different play experiences this holiday season. The company was acquired by MidOcean Partners (“MidOcean”), a premier middle market private equity firm focused on consumer and business services, in July 2015.

About KidKraft, Inc.

KidKraft is a global leader in award-winning products that are MADE FOR MAKE BELIEVE™. The company is committed to inspiring imaginative play creatively for children everywhere through dollhouses, kitchens, outdoor, vehicles, furniture, and toys. KidKraft’s high-quality products, designed for traditional play, are available at more than 2,800 retailers in more than 90 countries worldwide. KidKraft’s global headquarters are located in Dallas, Texas. For more information, visit www.kidkraft.com and follow @kidkrafttoys on Instagram.

About MidOcean Partners

MidOcean Partners is a premier New York-based alternative asset manager that specializes in middle market private equity and alternative credit investments. Since its inception in 2003, MidOcean Private Equity has managed approximately $4.8 billion of committed capital and has targeted investments in high-quality middle market companies in the consumer and business services sectors. MidOcean Credit Partners was launched in 2009 and manages approximately $8 billion across a series of alternative credit strategies, collateralized loan obligations (CLOs), and customized separately managed accounts as of September 30, 2019.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Litzky Public Relations on behalf of KidKraft
Kelsey Wheeler
Litzky Public Relations
201/222-9118
kidkraft@litzkypr.com

MidOcean Media Relations
Nathaniel Garnick/Amanda Klein
Gasthalter & Co.
212/257-4170
midocean@gasthalter.com

MidOcean Investor Relations
Allison Donohue
Investorrelations@midoceanpartners.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye